Wayne Kuznar

A higher OncotypeDX Genomic Prostate Score is associated with an increased risk of adverse pathology in patients who undergo delayed radical prostatectomy after a period of active surveillance.

Markers of bone metabolism improved in men with metastatic castration-refractory prostate cancer who received radium-223 (Xofigo) in addition to enzalutamide (XTANDI) compared with enzalutamide alone.

“The efficacy benefit and the favorable safety profile support aveluamb plus axitinib as a new first-line standard of care for advanced RCC,” says researcher Robert J. Motzer, MD.

Median overall survival for African-American men with advanced prostate cancer who are treated with docetaxel (Taxotere) is similar to that of Caucasian men, according to an analysis of pooled data from nine randomized phase III clinical trials.

Adding abiraterone acetate (ZYTIGA) to androgen deprivation therapy for the management of patients with metastatic castration-naïve prostate cancer does not increase medical resource utilization.

The decline occurred despite a consistent number of monthly clinical encounters with a primary diagnosis of hypogonadism.

Active surveillance as an initial management strategy for men with low-risk prostate cancer results in cost savings compared with immediate treatment, regardless of the treatment chosen.

A bladder-sparing approach for the treatment of muscle-invasive bladder cancer increases quality-adjusted life years compared with radical cystectomy in appropriately selected patients.